Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

NCT05184946 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Shandong First Medical University as lead sponsor.

NCT NCT05184946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05184946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
Lead sponsor
The Second Affiliated Hospital of Shandong First Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
October 9, 2021
Completion date
October 8, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer